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Abstract
Most brain gene expression studies of schizophrenia have been conducted in the frontal cortex or hippocampus. The extent
to which alterations occur in other cortical regions is not well established. We investigated primary visual cortex (Brodmann
area 17) from the Stanley Neuropathology Consortium collection of tissue from 60 subjects with schizophrenia, bipolar
disorder, major depression, or controls. We first carried out a preliminary array screen of pooled RNA, and then used RT-PCR
to quantify five mRNAs which the array identified as differentially expressed in schizophrenia (myelin basic protein [MBP],
myelin-oligodendrocyte glycoprotein [MOG], b-actin [ACTB], thymosin b-10 [TB10], and superior cervical ganglion-10
[SCG10]). Reduced mRNA levels were confirmed by RT-PCR for MBP, ACTB and TB10. The MBP reduction was limited to
transcripts containing exon 2. ACTB and TB10 mRNAs were also decreased in bipolar disorder. None of the transcripts were
altered in subjects with major depression. Reduced MBP mRNA in schizophrenia replicates findings in other brain regions
and is consistent with oligodendrocyte involvement in the disorder. The decreases in expression of ACTB, and the actin-
binding protein gene TB10, suggest changes in cytoskeletal organisation. The findings confirm that the primary visual
cortex shows molecular alterations in schizophrenia and extend the evidence for a widespread, rather than focal, cortical
pathophysiology.
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Introduction
Most neuropathological findings in schizophrenia have been
reported in the hippocampus or the dorsolateral prefrontal cortex
[1–3]. This concentration both reflects, and has contributed to, the
focus upon these regions as being of central pathophysiological
importance [4–7]. The neuropathological evidence includes a
contribution from many individual (e.g. [8–10]) and transcrip-
tomic (reviewed in [11,12]) studies of gene expression which have
shown molecular alterations in these regions. However, it is hard
to know whether there is a true predilection of pathology for these
areas, since other cortical regions have been far less well examined.
Such information is germane to the broader question as to
whether the cortical pathophysiology of psychosis is regionally
localised or is widespread. This in turn bears upon the issue of its
likely neurodevelopmental origins.
A good example of an area which might have been considered
neuropathologically ‘unaffected’ in psychosis is the occipital
cortex, including the primary visual or striate cortex (Brodmann
area [BA] 17). Yet morphometric [13,14] and gene expression
[15–18] data indicate that some structural and molecular
differences may occur therein. Indeed, in a microarray study
surveying several cortical regions, more transcripts were altered in
schizophrenia in BA17 than in dorsolateral prefrontal cortex [19].
Here, to address this question further, we report a study of gene
expression in BA17 of the Stanley Neuropathology Consortium
brain series. We used a two-stage approach. First, we pooled
mRNA from two batches of five subjects in each diagnostic group
and ran them on nylon arrays. We then took the transcripts which
met our criteria for differential expression in schizophrenia, and
carried out RT-PCR analysis of each mRNA individually in the
whole sample. Since this series of brains also includes bipolar
disorder and major depression subjects, we also had the
opportunity to address the diagnostic specificity of any alterations.
Methods
Post-mortem tissues
A block of frozen primary visual cortex (BA17) tissue was
provided from the 60 subjects comprising the Stanley Neuropa-
thology Consortium brain series [20] (Table 1). All material was
coded by the Stanley Medical Research Institute, and experiments
and analyses conducted blind to diagnostic and other information.
The brains were collected at the Uniformed Services University of
the Health Sciences (USUHS) between 1998 and 2004. The IRB
determined that IRB approval was not needed, since the subjects
were deceased and work was done on anonymized, numbered
specimens. Verbal consent to brain donation was obtained from
next-of-kin, by telephone, and was witnessed by two people who
signed a form verifying the fact. Subsequently, the next-of-kin was
contacted and interviewed to obtain further information about the
deceased. The work described in this paper was carried out in
accordance with the Declaration of Helsinki and with ethical
approval from Oxfordshire National Health Service Research
Ethics Committee B (#O02.040).
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RNA was obtained using the single-step method of acid
guanidinium thiocyanate-phenol-chloroform extraction [21] with
TRI reagent (Sigma, Poole, UK). The concentration of nucleic
acids was determined by absorbance spectrophotometry and RNA
quality was calculated from the ratio of the optical densities of 28s/
18s ribosomal bands on MOPS denaturing gel with ethidium
bromide. These values were confirmed with an Agilent Bioana-
lyzer (Agilent Technologies, South Queensferry, UK) for a subset
of 12 samples.
Approximately 10 mg of RNA was treated for 30 mins at 37uC
with 1U RQ1 RNase-Free DNase (Promega, Southampton, UK).
Because of the sensitivity of array studies to DNA contamination,
ribonuclease inhibitors were not used since initial tests suggested
that they inhibited the DNase activity. Optimal DNase concen-
tration to minimise RNA degradation but to eliminate DNA
contamination were determined in preliminary studies. The
solution was made up to 200 ml with nuclease free water and
mixed with 200 ml acid (pH 4.5) phenol-chloroform (9:1) and spun
for 5 mins. The top phase was mixed with 200 ml chloroform and
spun for 5 mins. The top phase was mixed with 20 ml 4M sodium-
acetate and 200 ml isopropanol and left to precipitate overnight at
4uC. The solution was spun for 15 mins at 4uC until an RNA
pellet formed. This pellet was washed twice in 75% ethanol, dried
for 10 mins, resuspended in nuclease free water, and stored at
270uC.
Gene Expression Arrays
We used the Atlas Human Neurobiology Array (BD Biosciences
Clontech), a double spotted nylon cDNA array with 593
neurobiological genes, several housekeeping genes, and plasmid
and bacteriophage DNAs as negative controls.
The arrays were run using RNA pooled from five subjects in
each diagnostic group, each subject contributing 2 mg. Pooling was
performed due to the cost of the arrays which precluded running
individual arrays. Pooling biological samples for arrays has been
shown to largely reflect the average of the individual samples, and
increases accuracy when few arrays are available to run in each
group [22]. We grouped the subjects together for pooling based
upon their RNA integrity [23,24]. We divided each diagnostic
group into three pools, reflecting the best, intermediate, and lowest
RNA quality (Table 2). Groups to be compared were hybridised to
arrays from the same lot.
The RNA was reverse transcribed and labelled with
32P as per
the manufacturer’s instructions with minor modifications: in a
total reaction volume of 20 ml there was a mixture of 2 ml5 6
reaction buffer, 2 ml1 0 6 deoxyribonucleotide triphosphate
(dNTP) mix, 3.5 ml of fresh [a-
32P]dATP (10 mCi/ ml), 1 ml
100 mM DTT, 2 ml Powerscript Moloney murine leukaemia virus
enzyme (MMLV), 5.5 ml of 5 or 10 mg of RNA, 2 ml1 0 6 CDS
primers. A master mix (buffer, dNTPs,
32P, DTT) was prepared at
room temperature. The RNA/106CDS primer mix was heated
at 70uC for 2 mins, then 50uC for 2 mins. This was added to the
master mix and MMLV and incubated at 50uC for 40 mins, with
the reaction ended with 2 ml termination mix.
Probes were diluted to 200 ml total volume with the included
buffer NT2 and added to the NucleoSpin Extraction Spin
Column, and centrifuged for 1 min. Three times 400 ml of buffer
NT3 was added to the column and it was spun for 1 min. 100 mlo f
buffer NE was then added and the column soaked for 2 mins. The
probe was eluted by centrifuging for 1 min. The radioactivity was
Table 1. Demographics of Stanley Neuropathology Consortium subjects.
Control (con) Schizophrenia (scz)
d Bipolar disorder (bip)
e Major depression (dep)
Subjects 15 15 15 15
Age (years) 48.1 (10.6) 44.5 (13.1) 42.3 (11.7) 46.5 (9.3)
Sex (M, F) 9, 6 9, 6 9, 6 9, 6
Brain pH 6.27 (0.24) 6.18 (0.24) 6.19 (0.23) 6.18 (0.22)
PMI (hours)
a 23.7 (9.9) 33.7 (14.6) 32.5 (16.1) 27.5 (10.7)
Freezer storage (months)
b 92.7 (7.5) 101.8 (7.8) 101.9 (5.6) 105.8 (9.7)
Hemisphere (R, L) 7, 8 6, 9 8, 7 6, 9
Suicides 0 4 9 7
Onset of illness (years) - 23.2 (8.0) 21.5 (8.3) 33.9 (13.3)
Duration of illness (y) - 21.8 (11.4) 21.4 (9.2) 12.7 (11.1)
Lifetime antipsychotics
c 0 52267 (62062) 20827 (24016) 0
Antipsychotics ever 0 14 12 0
Antidepressants ever 0 5 8 10
Mood stabilisers ever 0 0 10 2
Fresh brain weight (g) 1501 (164) 1472 (108) 1441 (172) 1458 (147)
Substance abuse history (1–3 scale)
d 1.13 (13,2,0) 1.67 (8,4,3) 2.00 (4,7,4) 1.53 (10,2,3)
Alcohol use history (1–3 scale)
e 1.27 (11,4,0) 1.69 (7,3,3) 2.08 (4,3,5) 1.64 (9,1,4)
Mean (SD) where appropriate.
aDiffers between groups (ANOVA P=0.147, planned contrasts scz.con P=0.043).
bDiffers between groups (ANOVA P=0.003, planned contrasts scz.con P=0.002 and bip.con P=0.002).
cFluphenazine equivalents (mg), d. 4 paranoid, 1 disorganised, 10 undifferentiated, e. 11 with psychotic features.
d1=none; 2=moderate; 3=severe. Differs between groups (ANOVA P=0.016, planned contrasts bip.con, P=0.010). The number of subjects in each category is shown
in brackets.
e1=low; 2=moderate; 3=high. Known for 54 subjects. The number of subjects in each category is shown in brackets.
doi:10.1371/journal.pone.0038211.t001
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32P was
acceptable for the best and medium quality RNA samples but very
poor for the worst quality RNA samples, confirming their
degradation.
For hybridization, 1 mg of heat denatured sheared salmon
testes DNA was added to 10 ml of BD ExpressHyb at 68uC and
the array pre-hybridized for 30 mins with continuous agitation at
68uC. Cot-1 DNA was added to the probe pool at a concentration
of 5% and the mixture incubated for 2 mins at 95–100uC for
2 mins. 5–10 million counts of probe were then added to the pre-
hybridization solution and the arrays hybridized for 18 hrs. Arrays
were then washed 4630 mins at 68uC in Wash Solution 1
(26SSC, 1% SDS) and 1630 mins in Wash Solution 2 (0.16SSC,
0.5% SDS), before a final rinse at room temperature in 26SSC
and then water.
Arrays were apposed to X-ray film (Biomax MS; Kodak, USA)
with an intensifying screen overnight, for 5 days and for 2 weeks,
at 270uC.
Array Analysis
The array films at different exposures were scanned (16bit
greyscale, 200 dpi) on a Microtek ScanMaker 5 with a transpar-
ency adapter and analysed using Atlas Image 2.7 (BD Biosciences
Clontech). All gene spots were inspected for signal bleed,
saturation, marks on the film or membrane, and for intensity
differences between the duplicate spots. The intensity threshold for
detection was set at twice background for the best quality RNA
arrays, and 1.5 times background for the medium quality RNA
arrays. The worst quality RNA arrays were not analysed due to
very low hybridization signals. Intensities were averaged across the
duplicate spots and corrected for background signal.
Two different normalisation strategies were used: normalisation
by the global sum of intensities on the array, and by the expression
of the three least variable housekeeping genes on the array.
Normalisation to the global sum assumes that the overall
expression between groups is the same, and is likely to be a fairly
conservative approach to detecting differentially expressed genes
when enough genes are detected. The least variable housekeeping
genes are determined by a stepwise process with the assumption
that they will represent a fairly constant proportion of transcripts
between samples. The log-ratio of each (non-saturated) house-
keeping gene to every other housekeeping gene is taken, and the
standard deviation of this value for each gene is taken between the
arrays. The mean of the log-ratios with every other gene is the
measure of variability for a gene. The gene with the highest value
is eliminated from the comparison and the log-ratios between the
remaining genes recalculated. This continues in a stepwise fashion
until three genes are left. The arithmetic mean of these three genes
was used to normalise the array. We implemented both
normalization methods using the associated software package
Atlas Image 2.7.
The criteria we used to identify transcripts differentially
expressed in schizophrenia and to select for subsequent RT-
PCR analysis were that the ratio of background corrected signal
intensity compared to controls was greater than 1.62 (up or down)
for both the best and medium quality pooled mRNA samples and
this was in the same direction in both pools. All genes thus
identified were re-checked to ensure that the differences were not
due to film saturation or other artefacts.
RT-PCR
Gene expression was measured by semi-quantitative reverse-
transcriptase polymerase chain reaction (RT-PCR) [25,26] with
target mRNA levels normalised to the geometric mean of three
housekeeping genes (porphobilinogen deaminase, PBGD; glycer-
aldehyde 3-phosphate dehydrogenase, GAPDH; ribosomal 18S,
Table 2. Demographic details of the three groups of the subjects pooled for the arrays.
Control Schizophrenia Bipolar Depression
A. Best Quality RNA Pools RNA Quality (28s/18s) 1.07 (.10) 1.00 (.12) .97 (.07) 1.08 (.11)
Age (years) 40.2 (8.8) 46.0 (14.0) 50.6 (9.2) 46.2 (13.1)
Sex (M, F) 2, 3 4, 1 3, 2 3, 2
Brain pH 6.32 (.24) 6.10 (.22) 6.30 (.19) 6.24 (.18)
PMI (hours) 25.8 (11.1) 31.0 (18.7) 21.0 (18.8) 19.2 (10.3)
Freezer storage (months) 94.8 (9.8) 104.6 (6.8) 100.8 (5.6) 95.6 (8.0)
B. Medium Quality RNA Pools RNA Quality (28s/18s)
a .92 (.02) .82 (.03) .84 (.03) .86 (.05)
Age (years) 54.4 (9.5) 44.4 (14.9) 42.6 (9.3) 47.0 (9.7)
Sex (M, F) 4, 1 3, 2 2, 3 3, 2
Brain pH 6.32 (.24) 6.34 (.29) 6.16 (.22) 6.20 (.24)
PMI (hours)
b 19.4 (18.6) 36.6 (9.0) 30.6 (7.9) 35.8 (10.7)
Freezer storage (months) 91.0 (6.0) 100.6 (5.1) 100.2 (17.3) 98.2 (12.3)
C. Worst Quality RNA Pools RNA Quality (28s/18s) .72 (.10) .63 (.11) .52 (.01) .59 (.11)
Age (years) 49.6 (10.0) 43.2 (13.3) 33.8 (11.5) 46.4 (6.2)
Sex (M, F) 3, 2 2, 3 4, 1 3, 2
Brain pH 6.16 (.26) 6.04 (.18) 6.10 (.28) 6.10 (.22)
PMI (hours) 26.0 (10.7) 33.4 (17.2) 39.0 (12.4) 27.4 (3.3)
Freezer storage (months) 92.2 (7.7) 100.2 (11.1) 104.8 (3.4) 93.6 (9.9)
Values are mean (S.D.).
aDiffers between groups (ANOVA p=.002; planned contrasts scz,con p,.0005, bip,con p=.002, dep,con p=.010).
bDiffers between groups (ANOVA p=.136; planned contrasts scz.con p=.040, dep.con p=.040).
doi:10.1371/journal.pone.0038211.t002
Visual Cortex Gene Expression in Schizophrenia
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38211r18s) amplified in separate reactions on the same reverse-
transcribed template [27,28].
5 mg of RNA per subject was treated with RQ1 RNase-Free
DNase (Promega, Southampton, UK) and reverse transcribed with
Moloney murine leukaemia virus (mmLV) enzyme (Promega).
All primers were obtained from Eurogentec (Southampton,
UK). Optimum conditions, including the linear region of
amplification, were determined for each primer. Most primers
used three-step PCR reactions consisting of an initial denaturing
step (5 mins at 94uC) then a number of cycles (determined for each
primer) of three phases: denaturing (94uC for 45 s), annealing
(temperature determined for each primer, 1 min unless otherwise
indicated) and extension (72uC for 1 min). These cycles were
followed by a final extension step (72uC for 3 mins). Reactions
using a quick two-step PCR protocol consisted of denaturing
(94uC for 1 min) followed by a number of cycles of denaturing
(94uC for 30 s) and combined annealing and extension phases
(1 min). Primer sequences and the details of amplification are
given in Table S1.
PCR reactions were carried out using puReTaq Ready-To-Go
PCR Beads (Amersham Biosciences, Little Chalfont, UK). All
primer products were confirmed by sequencing, and a subset were
also confirmed by restriction enzyme digest. PCR products were
fractionated with agarose gels and ethidium bromide and semi-
quantitatively measured from the UV optical density of bands
using an Alphaimager 3400 gel imager (Genetic Research
Instrumentation, Braintree, UK).
All statistical tests were two-tailed and carried out at an
uncorrected alpha of 5%. The default analysis was analysis of
variance (ANOVA) with planned comparisons of the control
subjects versus the three other diagnostic groups. Shapiro-Wilk
and Levene’s tests (for normality and homogeneity of variance
respectively) were carried out on the dependent variables at
a=0.05. S ˇida ´k tests were performed for post-hoc contrasts. If
normality or homogeneity of variance were violated the variable
was log-transformed and re-tested. If the log-transform failed to
correct the distribution a Kruskal-Wallis (KW) non-parametric
ANOVA was used. For two-sample comparisons, the t-test or
Wilcoxon-Mann-Whitney (WMW) test was used as appropriate.
We also inspected for correlations between each normalised
mRNA and potential confounding variables (28s/18s ribosomal
ratio, age, pH, post mortem interval, and freezer storage time).
Any variable showing a significant Pearson (or Spearman where
appropriate) correlation at a=0.05 (and checked visually) was
included in an ANCOVA. In secondary analyses, further
correlations and contrasts were assessed for other demographic
variables including medication history, alcohol and substance use,
brain hemisphere, gender, onset and duration of illness, family
history of psychiatric illness, and suicide.
Results
Results from the pooled arrays
We identified 157 transcripts as being above our threshold for
reliable detection on both the high and medium quality pooled
RNA arrays. As noted, the low quality arrays were not analysed
due to poor
32P incorporation and low hybridization signals.
Five genes met our criteria for being differentially expressed in
schizophrenia compared to the control subjects. All were
decreased in the disorder. Four of the transcripts were significant
both by global sum normalization and housekeeping gene
normalization (myelin-oligodendrocyte glycoprotein [MOG]);
thymosin b-10 [TB10, TMSB10]; b-actin [ACTB]); superior
cervical ganglion-10 [SCG10; STMN2]). The fifth, myelin basic
protein [MBP] was significantly altered on the high quality array
using global sum normalization, and on the medium quality array
by housekeeping gene normalization. We then examined these five
transcripts in the pooled RNA from subjects with bipolar disorder
and with major depression. Relative to the healthy controls, SCG-
10 and TB10 mRNAs were decreased in bipolar disorder, and
ACTB decreased in major depression. These five transcripts,
together with the three reference genes, were taken forward for
analysis by RT-PCR.
Primary analyses of RT-PCR data
All sixty subjects (Table 1) were included in the RT-PCRs. The
primary analyses for the normalised expression of each target
transcript are summarised in Table 3, and positive findings
illustrated in Figure 1. None of the reference transcripts, nor the
geometric mean thereof, differed between diagnostic groups.
MBP expression (Table 3; Figure 1A) was reduced in
schizophrenia (ANOVA P=0.004; planned contrast schizophre-
nia,controls, P=0.006). Post hoc testing showed that MBP
mRNA in schizophrenia was reduced compared to major
depression (S ˇida ´k P=0.003) but not to bipolar disorder (S ˇida ´k
P=0.195). Tkachev at al [29] found that reductions in MBP
expression in schizophrenia were specific for transcripts containing
exon 2, so we used a second set of MBP primers bridging exons 1
and 3 and found no significant differences in MBP mRNA (all
P.0.25). Therefore, the reduction in MBP expression in
schizophrenia was specific for transcripts containing exon 2.
ACTB expression (Table 3; Figure 1B) was reduced in
schizophrenia (ANOVA P=0.016; planned contrast scz,con
P=0.005) and bipolar disorder (planned contrast bip,con
P=0.008) compared to controls. Post-hoc tests did not reveal
any significant differences between the diagnostic groups (S ˇida ´k all
P.0.1). Merging the bipolar disorder and major depression
subjects also shows a significant reduction in the combined mood
disorders group compared to controls (ANOVA P=0.012;
planned contrast mood,con P=0.017).
TB10 expression (Table 3; Figure 1C) was reduced in
schizophrenia (ANOVA P=0.045; planned contrast scz,con
P=0.018) and bipolar disorder (planned contrast bip,con
P=0.014) compared to controls. Post-hoc tests did not reveal
any further differences (S ˇida ´k, all P.0.1). Combining the bipolar
disorder and major depression subjects also shows a reduction
compared to controls (ANOVA P=0.042; planned contrast
mood,con P=0.035).
MOG and SCG10 mRNAs showed no differences between
cases and controls by RT-PCR (Table 3; all P.0.1).
Correlations and secondary analyses
ACTB mRNA was affected by alcohol and substance use. One-
way ANOVA revealed a main effect of alcohol use using the three
point scale (Table 1; P=0.038), with ACTB mRNA being
decreased in the medium (P=0.051) and highest (P=0.018) use
groups compared to the lowest use group. Inclusion of alcohol use
in the main ANOVA rendered the diagnosis effect a trend
(P=0.07) with the planned contrasts remaining significant for
scz,con (P=0.012) and as a trend for bip,con (P=0.054). Thus,
alcohol use and a diagnosis of schizophrenia were both associated
with decreased ACTB mRNA. Classifying subjects by their history
of substance abuse revealed a significant reduction in ACTB
expression (P=0.028), but including substance abuse in the main
ANOVA showed no significant effect due to substance abuse
(P.0.1) while the reduced ACTB mRNA in schizophrenia
remained significant (planned contrast schizophrenia,controls,
P=0.031) with a trend for a reduction in bipolar subjects
Visual Cortex Gene Expression in Schizophrenia
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mRNA is driven primarily by confounding with psychiatric
diagnosis. There were no other significant effects of alcohol use,
or of substance misuse, on the mRNAs.
Brain hemisphere, sex, and suicide showed no significant effects,
nor interactions with diagnosis, on expression of any of the
mRNAs. The normalised mRNAs showed very few correlations
with continuous demographic and other variables. The main
exceptions were that the ribosomal ratio (a measure of RNA
integrity) correlated with normalised SCG10 mRNA (Spearman
rs=0.319, P=0.013), and MOG mRNA (rs=0.325, P=0.011),
and age correlated inversely with MOG mRNA (Spearman
rs=20.312, P=0.015). Inclusion of the respective variable as a
covariate did not significantly affect the result of the primary
analyses.
With regard to disease-associated variables, in the schizophrenia
group, TB10 mRNA correlated negatively with age of onset of
illness (r=20.555, P=0.032) and positively with lifetime antipsy-
chotic intake (Figure 1D; r=20.624, P=0.013); the latter also
correlated with TB10 mRNA when the bipolar disorder subjects
who had taken antipsychotics were included (r=20.429,
Figure 1. Relative abundance of selected mRNAs in the visual cortex in control subjects and subjects with schizophrenia, bipolar
disorder, or major depression. A. Myelin basic protein (MBP) mRNA. B: b-actin (ACTB) mRNA. C: Thymosin b-10 (TB10) mRNA. D: Correlation
between TB10 mRNA and antipsychotic drug exposure in patients with schizophrenia (squares) and bipolar disorder (triangles). Values are normalised
to the geometric mean of the three housekeeping genes. ** P,0.01, * P,0.05. See also Table 3.
doi:10.1371/journal.pone.0038211.g001
Table 3. Relative abundance of mRNAs by RT-PCR, normalised to the geometric mean of the three housekeeping genes.
Con (n=15) Scz (n=15) Bip (n=15) Dep (n=15)
Gene ANOVA P-Value Mean (SD) Mean (SD) P-Value Mean (SD) P-Value Mean (SD) P-Value
MBP 0.004** 0.597 (0.187) 0.444 (0.231) 0.006** 0.553 (0.197) 0.502 0.657 (0.160) 0.368
MBP (DE2 ) 0 . 2 5 8
1 0.676 (0.221) 0.619 (0.305) 0.174
2 0.556 (0.128) 0.079
3 0.611 (0.148) 0.346
3
ACTB 0.016* 0.443 (0.125) 0.332 (0.151) 0.005** 0.320 (0.081) 0.008** 0.373 (0.101) 0.137
TB10 0.045* 0.836 (0.352) 0.628 (0.167) 0.018* 0.621 (0.178) 0.014* 0.703 (0.148) 0.230
SCG10 0.703
1 1.05 (0.212) 1.12 (0.200) 0.461
2 1.07 (0.248) 0.567
2 1.09 (0.288) 0.305
2
MOG 0.881
1 1.58 (0.162) 1.48 (0.263) 0.249
3 1.57 (0.296) 0.902
2 1.53 (0.208) 0.775
2
P-values for individual psychiatric groups are comparisons with the control group.
1Kruskal-Wallis ANOVA.
2Wilcoxon-Mann-Whitney test.
3t-test.
**P,0.01,
*P,0.05.
doi:10.1371/journal.pone.0038211.t003
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nor with duration of illness, were observed.
Discussion
To investigate gene expression in primary visual cortex in
schizophrenia, we used an initial array screen of pooled RNA,
followed by RT-PCR of transcripts thereby identified as differen-
tially expressed. RT-PCR confirmed reductions of MBP, ACTB
and TB10, but not MOG or SCG10, in schizophrenia. ACTB and
TB10 were also decreased in bipolar disorder.
MBP is an abundant component of the oligodendrocyte myelin
membrane, alternatively spliced from the Golli-MBP gene [30,31].
MBP is critical for myelin membrane biogenesis and for regulating
entry of other proteins into the membrane sheets [32]. Microarray
studies of schizophrenia and bipolar disorder have frequently
implicated myelin-related genes including MBP, and MOG
[11,12,29,33,34]. Together with evidence for reductions in
oligodendrocyte number, these data have been major contributors
to the hypothesis that oligodendrocyte dysfunction is important in
pathogenesis [35,36]. However, most prior studies were in frontal
cortex, and to our knowledge the present data are the first to
suggest that a similar process might occur in occipital cortex. Our
study confirmed the specificity of MBP mRNA changes to
transcripts containing exon 2 [29]. The basis for this isoform
selectivity, and the functionality of exon 2-containing MBP
variants are unknown, although it is of interest that this variant
is selectively regulated by the Src-protein tyrosine kinase member
Fyn [37], a key player in oligodendrocyte maturation and
myelination [38].
ACTB (b-actin) serves a structural and motile role in all cell
lineages, with actin polymerisation affecting many processes
including axonal growth [39,40], oligodendrocyte myelination
[41] and membrane transport [42]. Actin polymerisation is
intimately involved in synaptic plasticity and development of
dendritic spines [43–47] and it is preferentially found there
[47,48], as well as serving a structural role in other parts of the
synaptic complex [49] particularly in excitatory synapses [50].
ACTB also has a range of other roles related to the cytoskeleton.
Given its pleiotropic nature, reduction of ACTB in schizophrenia
may have a range of causes and consequences. For example,
expression of other actin-related or cytoskeletal proteins has been
implicated in schizophrenia and bipolar disorder [33,51–53], and
several schizophrenia susceptibility genes interact with actin and
the cytoskeleton, including DISC1 [54], calcineurin [55], Akt1
[56] and dysbindin [57]. Or, the reduction in ACTB mRNA may
be a correlate of differences in cellular or dendritic morphology
and cytoarchitecture [1–3,13,14], which may itself be in part
genetically influenced [58,59].
ACTB is often used as a normalizing, or housekeeping, gene.
Our finding that it is decreased in visual cortex in schizophrenia
and bipolar disorder indicates that caution is required in this
respect, notwithstanding negative findings in two prior studies of
schizophrenia in this region [18,60] and the equivocal [23] or
negative results [18,24,61,62] in other cortical regions. The effect
of alcohol and substance use on ACTB expression suggests that
this factor should also be examined if ACTB is to be used as a
housekeeping gene in human brain.
Thymosin b-10 is a small polypeptide, implicated primarily in
cancer biology, including motility, apoptosis, and angiogenesis,
and in inflammation [63,64]. It is expressed in neurons and in
oligodendrocytes [65,66], and is abundant in fetal brain [67,68].
Its specific neural functions are unclear, but it is notable that its
primary role is to sequester actin, by binding to actin monomers
and regulating actin polymerisation [64]. As such, the decreases in
TB10 and ACTB may be related, potentially in an antagonistic
way. That is, reduced b-actin levels would result in reduced
globular-actin (G-actin) and a consequent reduction in the
polymerisation of filamentous-actin (F-actin); reduced TB10 would
result in less G-actin being sequestered, and consequently promote
F-actin formation. Therefore, the reduction in TB10 expression
could be compensatory for reductions in b-actin, or vice versa.
Further studies are needed to tease apart the functional interplay
between ACTB and TB10 to clarify the interpretation of the
present findings. Intriguingly, MBP also binds to actin [69] and
affects actin polymerization [70]. Hence one may speculate that
the reductions in ACTB, TB10 and MBP expression may all
reflect a common process, or convergent functional sequelae.
Our study had several limitations. First, the arrays had very
limited coverage by current microarray standards (with only 157
transcripts reliably detected) so many transcripts could be altered
in schizophrenia and be undetected here, including other myelin
or cytoskeletal transcripts. Our finding of five altered transcripts
(,3% of total) is comparable to the proportion affected in
contemporary microarray studies of psychosis, Second, we did not
confirm whether changes in abundance were seen in the encoded
proteins. Third, although we inspected for potential confounding
variables – and controlled for them statistically where appropriate
– we cannot rule out such factors entirely.
In summary, we confirm that the visual cortex is not ‘spared’ by
the molecular neuropathology of schizophrenia, in that the
expression of several genes is altered. Our results extend the list
of affected transcripts therein to include myelin basic protein and
two b-actin-related genes. Overall, the emerging picture is that all
areas of neocortex surveyed thus far in schizophrenia show, to at
least some extent, evidence of involvement. One may also infer
that the neurodevelopmental or other processes which underlie the
changes also affect processes common to the neocortex, in addition
to others which may be distinctive to specific cortical areas,
circuits, or cell populations. Finally, the finding that two of the
transcripts were changed similarly in bipolar disorder as in
schizophrenia is consistent with the overlapping gene expression
profiles between these two disorders seen in other regions [71,72],
and provides the first evidence to our knowledge that the
molecular neuropathology of bipolar disorder [73,74] may likewise
involve the occipital cortex.
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